ADC Therapeutics S.A.

NYSE:ADCT

Biotechnology

Healthcare
$1.37 -1.35%

-$0.02 today

Market cap
$192.71M
Beta
1.77
P/E (TTM)
-1.2
EPS (TTM)
-$0.89
52W Low $0.78High $4.98

Volume 1.17M

Average 1.68M

ADCT Minority Interest

The portion of consolidated subsidiaries' equity owned by outside shareholders.

ADC Therapeutics S.A.NYSE: ADCT

Minority Interest · Q1 FY2026 · quarter ended Mar 2026

Minority interest remains negative

Q1 FY2026 minority interest was $0, compared with $0 a year earlier.

Context

  • Minority interest amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Minority interest increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoMar 2025
$0— since
Minority Interest past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Minority Interest history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Minority Interest vs competitors

How ADCT compares with its peers on the latest reported figures

  • ADCT's Mar 2026 minority interest of $0 is the highest of the 10 companies compared; the peer median is $0.
  • Minority interest amounts to 0.0% of total assets for ADCT, versus a peer median of 0.0%.
ADCT Competitors Peer median
Minority Interest for ADCT and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ADCTADC Therapeutics S.A.Mar 2026$0 ——0.0%
OMEROmeros CorporationMar 2026$0 ——0.0%
LXRXLexicon Pharmaceuticals, Inc.Mar 2026$0 ——0.0%
ALMSAlumis Inc. Common StockJun 2026$0 ——0.0%
FDMT4D Molecular Therapeutics, Inc.Mar 2026$0 ——0.0%
AUTLAutolus Therapeutics plcMar 2026$0 ——0.0%
BCYCBicycle Therapeutics plcMar 2026$0 ——0.0%
QSIQuantum-Si incorporatedMar 2026$0 ——0.0%
NMRANeumora Therapeutics, Inc. Common StockMar 2026$0 ——0.0%
LCTXLineage Cell Therapeutics, Inc.Mar 2026-$1.18M +14.1%—1.1%
Peer median (excluding ADCT) $0+14.1%—0.0%

Competitors are the stored peer set for ADCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents466.54M326.44M278.6M250.87M261.34M
Short-term Investments00000
Net Receivables31.06M72.97M25.18M20.32M29.12M
Inventory11.12M12.07M16.18M18.39M4.18M
Other Current Assets1.11M199K5.99M9.45M11.7M
Total Current Assets525.18M434.98M336.29M307.39M306.34M
Property, Plant & Equipment (Net)11.23M10.26M16.13M13.43M1.3M
Goodwill00000
Intangible Assets13.58M14.36M000
Long-term Investments41.24M7.61M1.65M00
Tax Assets26.05M37.1M000
Other Non-current Assets693K(13.46M)711K1.16M15.52M
Total Non-current Assets92.79M55.88M18.49M14.59M16.82M
Total Assets617.97M490.86M354.78M321.98M323.15M
Account Payables12.08M12.35M15.57M18.03M9.18M
Short-term Debt6.58M12.47M003M
Tax Payables3.75M0000
Deferred Revenue00000
Other Current Liabilities14.11M4.08M37.94M47.47M57.99M
Total Current Liabilities73.94M81.94M67.67M80.47M70.16M
Long-term Debt125.1M109.71M112.73M113.63M436.01M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)23.54M23.54M0320.09M0
Other Non-current Liabilities222.32M189.65M312.45M2.43M2.81M
Total Non-current Liabilities377.95M329.47M435.36M444.15M438.82M
Total Liabilities451.88M411.41M503.03M524.62M508.98M
Common Stock6.45M7.31M7.31M8.43M11.08M
Retained Earnings(924.89M)(1.1B)(1.34B)(1.49B)(1.64B)
Accumulated OCI102.83M1.82M(93K)(1.42M)(517K)
Other Stockholders Equity00000
Minority Interest00000
Total Equity166.09M79.45M(148.25M)(202.64M)(185.83M)
Total Debt139.7M129.85M124.38M123M439.01M
Net Debt(326.85M)(196.59M)(154.22M)(127.87M)177.67M

ADC Therapeutics S.A.

NYSE:ADCT

Intrinsic Alpha fair value

Locked

Current Price

$1.37

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.